Met and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Kanteti, Rajani ^a   Dhanasingh, Immanuel ^a   Kawada, Ichiro ^a   Lennon, Frances E ^a   Arif, Qudsia ^a   Bueno, Raphael ^b   Hasina, Rifat ^a   Husain, Aliya N ^a   Vigneswaran, Wickii ^a   Seiwert, Tanguy ^a   Kindler, Hedy L ^a   Salgia, Ravi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APITOLISIB; CRIZOTINIB; CYCLIN D1; DACTOLISIB; FOCAL ADHESION KINASE; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PAXILLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PICTILISIB; PROTEIN KINASE B; S6 KINASE; SCATTER FACTOR RECEPTOR; TIVANTINIB; 1-(4-((2-(2-AMINOPYRIMIDIN-5-YL)-7-METHYL-4-MORPHOLINOTHIENO(3,2-D)PYRIMIDIN-6-YL)METHYL)PIPERAZIN-1-YL)-2-HYDROXYPROPAN-1-ONE; 2 PYRROLIDONE DERIVATIVE; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; IMIDAZOLE DERIVATIVE; MET PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL MOTILITY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MESOTHELIOMA CELL LINE; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WOUND HEALING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; NUDE MOUSE; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; PTEN PHOSPHOHYDROLASE; PYRIMIDINES; PYRROLIDINONES; QUINOLINES; TOR SERINE-THREONINE KINASES; WOUND HEALING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907189396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105919     Document Type: Article

References (54)

1. Tsiouris A, Walesby RK (2007) Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol 4: 344-352.
2. Britton M (2002) The epidemiology of mesothelioma. Semin Oncol 29: 18-25.
3. De Luca A, Baldi A, Esposito V, Howard CM, Bagella L, et al. (1997) The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med 3: 913-916.
4. Dogan AU, Baris YI, Dogan M, Emri S, Steele I, et al. (2006) Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 66: 5063-5068.
5. Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK (2006) The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 107: 108-115.
6. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644.
7. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, et al. (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889.
8. Campbell NP, Kindler HL (2011) Update on malignant pleural mesothelioma. Semin Respir Crit Care Med 32: 102-110.
9. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411: 355-365.
10. Dazzi H, Hasleton PS, Thatcher N, Wilkes S, Swindell R, et al. (1990) Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 61: 924-926.
11. Hoang CD, Zhang X, Scott PD, Guillaume TJ, Maddaus MA, et al. (2004) Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res 64: 7479-7485.
12. Pass HI, Robinson BW, Testa JR, Carbone M (1999) Emerging translational therapies for mesothelioma. Chest 116: 455S-460S.
13. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, et al. (2006) Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66: 352-361.
14. Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, et al. (2009) Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 30: 1097-1105.
15. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, et al. (2008) Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68: 9479-9487.
16. Munshi N, Jeay S, Li Y, Chen CR, France DS, et al. (2010) ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9: 1544-1553.
17. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, et al. (2012) PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 14: 129-138.
18. Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, et al. (2012) Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol 23: 2399-2408.
19. Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R (2009) The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 315: 485-497.
20. Cao P, Maira SM, Garcia-Echeverria C, Hedley DW (2009) Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 100: 1267-1276.
21. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, et al. (2010) The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 16: 3628-3638.
22. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, et al. (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68: 8022-8030.
23. Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, et al. (2011) GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 10: 2426-2436.
24. Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, et al. (2009) PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest 89: 301-314.
25. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, et al. (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65: 1479-1488.
26. Saleh SN, Albert AP, Large WA (2009) Activation of native TRPC1/C5/C6 channels by endothelin-1 is mediated by both PIP3 and PIP2 in rabbit coronary artery myocytes. J Physiol 587: 5361-5375.
27. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
28. Ma PC, Kijima T,Maulik G, Fox EA, Sattler M, et al. (2003) c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63: 6272-6281.
29. Bhalla KN (2003) Microtubule-targeted anticancer agents and apoptosis. Oncogene 22: 9075-9086.
30. Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6: 24.
31. Cedres S, Montero MA, Martinez P, Martinez A, Rodriguez-Freixinos V, et al. (2012) Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 77: 192-198.
32. de Melo M, Gerbase MW, Curran J, Pache JC (2006) Phosphorylated extracellular signal-regulated kinases are significantly increased in malignant mesothelioma. J Histochem Cytochem 54: 855-861.
33. Miyoshi S, Hamada H, Hamaguchi N, Kato A, Katayama H, et al. (2012) Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo. Int J Oncol 41: 449-456.
34. Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, et al. (2011) Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer 117: 361-371.
35. Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, et al. (2011) Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 286: 20666-20676.
36. Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, et al. (2013) Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 19: 2381-2392.
37. Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, et al. (2013) Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 73: 3087-3096.
38. Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, et al. (2006) EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51: 207-215.
39. Liu R, Ferguson BD, Zhou Y, Naga K, Salgia R, et al. (2013) EphB4 as a therapeutic target in mesothelioma. BMC Cancer 13: 269.
40. Chen TH, Chan PC, Chen CL, Chen HC (2011) Phosphorylation of focal adhesion kinase on tyrosine 194 by Met leads to its activation through relief of autoinhibition. Oncogene 30: 153-166.
41. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, et al. (2008) Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res 68: 132-142.
42. Bi Y, Han Y, Bi H, Gao F, Wang X (2013) miR-137 impairs the proliferative and migratory capacity of human non-small cell lung cancer cells by targeting paxillin. Hum Cell.
43. Gandin V, Senft D, Topisirovic I, Ronai ZA (2013) RACK1 Function in Cell Motility and Protein Synthesis. Genes Cancer 4: 369-377.
44. Miller TW, Rexer BN, Garrett JT, Arteaga CL (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13: 224.
45. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
46. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
47. Fei SJ, Zhang XC, Dong S, Cheng H, Zhang YF, et al. (2013) Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells. PLoS One 8: e69104.
48. Herrera VA, Zeindl-Eberhart E, Jung A, Huber RM, Bergner A (2011) The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines. Anticancer Res 31: 849-854.
49. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, et al. (2009) NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 8: 2204-2210.
50. Roper J, Richardson MP, Wang WV, Richard LG, Chen W, et al. (2011) The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One 6: e25132.
51. Xu CX, Zhao L, Yue P, Fang G, Tao H, et al. (2011) Augmentation of NVPBEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther 12: 549-555.
52. Hoda MA, Mohamed A, Ghanim B, Filipits M, Hegedus B, et al. (2011) Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. J Thorac Oncol 6: 852-863.
53. Humbert M, Medova M, Aebersold DM, Blaukat A, Bladt F, et al. (2013) Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. Biochem Biophys Res Commun 431: 264-269.
54. Sharma N, Adjei AA (2011) In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs. Ther Adv Med Oncol 3: S37-50.